OBJECTIVE: The abnormal expression of fragile histidine triad (FHIT) gene has been frequently reported in a variety of epithelial malignancies including cervical carcinoma. Furthermore, in a recent study it was proposed that transcriptional inactivation of FHIT, as a consequence of aberrant 5'-CpG island methylation, plays an important role in the carcinogenesis of human cervical carcinoma. The authors sought to determine whether abnormal FHIT transcription occurs in human cervical carcinoma, and if so, whether this abnormal expression is associated with aberrant 5'-CpG island methylation. In addition, the clinical significance of FHIT inactivation was investigated in Korean women with cervical cancer. METHODS: To examine for abnormal transcripts of the FHIT gene, quantitative RT-PCR, genomic DNA-PCR and nonisotopic RT-PCR-SSCP analysis were performed using the standard method. The methylation status was determined by methylation specific PCR and bisulfite DNA sequencing. RESULTS: The FHIT gene was down-regulated in 15 of 58 (25.9%) cervical carcinomas. FHIT promoter hypermethylation was detected in 15 of 15 (100%) abnormally expression in cervical carcinomas. Bisulfite DNA sequencing confirmed these findings and a significant correlation was found between CpG site hypermethylation and low FHIT expression. However, no significant correlation was found between reduced FHIT expression and clinicopathological characteristics. CONCLUSION: In this study, FHIT inactivation in cervical cancer was found to be strongly correlated with 5'-CpG island hypermethylation rather than a genetic alteration. Furthermore, no significant relation was found between a lack of FHIT expression and the prognostic factors of cervical cancer in our Korean cohort.
OBJECTIVE: The abnormal expression of fragile histidine triad (FHIT) gene has been frequently reported in a variety of epithelial malignancies including cervical carcinoma. Furthermore, in a recent study it was proposed that transcriptional inactivation of FHIT, as a consequence of aberrant 5'-CpG island methylation, plays an important role in the carcinogenesis of humancervical carcinoma. The authors sought to determine whether abnormal FHIT transcription occurs in humancervical carcinoma, and if so, whether this abnormal expression is associated with aberrant 5'-CpG island methylation. In addition, the clinical significance of FHIT inactivation was investigated in Korean women with cervical cancer. METHODS: To examine for abnormal transcripts of the FHIT gene, quantitative RT-PCR, genomic DNA-PCR and nonisotopic RT-PCR-SSCP analysis were performed using the standard method. The methylation status was determined by methylation specific PCR and bisulfite DNA sequencing. RESULTS: The FHIT gene was down-regulated in 15 of 58 (25.9%) cervical carcinomas. FHIT promoter hypermethylation was detected in 15 of 15 (100%) abnormally expression in cervical carcinomas. Bisulfite DNA sequencing confirmed these findings and a significant correlation was found between CpG site hypermethylation and low FHIT expression. However, no significant correlation was found between reduced FHIT expression and clinicopathological characteristics. CONCLUSION: In this study, FHIT inactivation in cervical cancer was found to be strongly correlated with 5'-CpG island hypermethylation rather than a genetic alteration. Furthermore, no significant relation was found between a lack of FHIT expression and the prognostic factors of cervical cancer in our Korean cohort.
Authors: K Hibi; T Takahashi; K Yamakawa; R Ueda; Y Sekido; Y Ariyoshi; M Suyama; H Takagi; Y Nakamura; T Takahashi Journal: Oncogene Date: 1992-03 Impact factor: 9.867
Authors: Eun Ju Lee; Bo Bin Lee; Jin Wook Kim; Young Mog Shim; I Hoseok; Joungho Han; Eun Yoon Cho; Joobae Park; Duk-Hwan Kim Journal: Eur J Cancer Date: 2006-03-27 Impact factor: 9.162
Authors: T C Krivak; J W McBroom; J Seidman; D Venzon; B Crothers; P J MacKoul; G S Rose; J W Carlson; M J Birrer Journal: Cancer Res Date: 2001-06-01 Impact factor: 12.701
Authors: L D Barnes; P N Garrison; Z Siprashvili; A Guranowski; A K Robinson; S W Ingram; C M Croce; M Ohta; K Huebner Journal: Biochemistry Date: 1996-09-10 Impact factor: 3.162
Authors: S Nakagawa; H Yoshikawa; M Kimura; K Kawana; K Matsumoto; T Onda; N Kino; M Yamada; T Yasugi; Y Taketani Journal: Br J Cancer Date: 1999-02 Impact factor: 7.640
Authors: Malin Lando; Christina S Fjeldbo; Saskia M Wilting; Barbara C Snoek; Eva-Katrine Aarnes; Malin F Forsberg; Gunnar B Kristensen; Renske Dm Steenbergen; Heidi Lyng Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Jean-Pierre Issa; Razelle Kurzrock; Ignacio I Wistuba; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta; Marcelo Aldaz Journal: Clin Epigenetics Date: 2014-07-03 Impact factor: 6.551